Start for free
Start for free
Oberland Capital logo

Oberland Capital

North America, New York, United States, New York

Description

Oberland Capital provides innovative financing solutions to companies .

Investor Profile

Oberland Capital has made 13 investments, with 2 in the past 12 months and 92% as lead.

Stage Focus

  • Post Ipo Equity (38%)
  • Post Ipo Debt (31%)
  • Series Unknown (15%)
  • Series A (8%)
  • Debt Financing (8%)

Country Focus

  • United States (85%)
  • Denmark (8%)
  • Switzerland (8%)

Industry Focus

  • Health Care
  • Biotechnology
  • Pharmaceutical
  • Therapeutics
  • Health Diagnostics
  • Biopharma
  • Medical
  • Emergency Medicine
  • Hospitality
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Oberland Capital frequently co-invest with?

BioBrit
BioBrit
North America, California, United States, La Jolla
Co-Investments: 1
Samsara BioCapital
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 1
BioRock Ventures Name
BioRock Ventures Name
North America, California, United States, Palo Alto
Co-Investments: 1
CAM Capital
CAM Capital
North America, New York, United States, New York
Co-Investments: 1
Polaris Partners
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1

Which angels does Oberland Capital often collaborate with?

CM
Charlie McDermott
North America, California, United States
Shared Deals: 1

What are some of recent deals done by Oberland Capital?

Verastem Oncology

Needham, Massachusetts, United States

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

BiopharmaBiotechnologyPharmaceutical
Post Ipo DebtJan 13, 2025
Amount Raised: $75,000,000
Verastem Oncology

Needham, Massachusetts, United States

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityJan 13, 2025
Amount Raised: $7,500,000
ImmunityBio

Culver City, California, United States

ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.

Health CareHealth DiagnosticsTherapeutics
Post Ipo DebtJan 2, 2024
Amount Raised: $200,000,000
ImmunityBio

Culver City, California, United States

ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.

Health CareHealth DiagnosticsTherapeutics
Post Ipo EquityJan 2, 2024
Amount Raised: $10,000,000
Helsinn Healthcare

Lugano, Ticino, Switzerland

Helsinn is a privately-owned pharmaceutical group with headquarters in Lugano, Switzerland.

Health CarePharmaceuticalTherapeutics
Series UnknownJan 10, 2023
Zealand Pharma

Copenhagen, Hovedstaden, Denmark

Zealand Pharma is a biotechnology company that offers scientific expertise in turning peptides into medicines.

BiopharmaBiotechnologyHealth Care
Post Ipo DebtDec 14, 2021
Amount Raised: $200,000,000
Centessa Pharmaceuticals

Cambridge, Massachusetts, United States

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.

BiotechnologyPharmaceutical
Post Ipo DebtOct 4, 2021
Amount Raised: $300,000,000
Esperion

Ann Arbor, Michigan, United States

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.

BiotechnologyHealth CareMedicalPharmaceutical
Post Ipo EquityApr 26, 2021
Amount Raised: $50,000,000
Mirum Pharmaceuticals

Foster City, California, United States

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityDec 9, 2020
Amount Raised: $10,000,000
Primmune Therapeutics

San Diego, California, United States

Primmune Therapeutics is a Biotechnology company.

BiotechnologyHealth Care
Series AOct 27, 2020
Amount Raised: $27,400,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator